Victoza® is a GLP-1 analog with 97% similarity to native GLP-1 (7-37)a.
The Victoza® mechanism of action

Consider a once-weekly GLP‑1 RA therapy
Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.
See how Victoza® works in multiple systems in the body1
aGLP-1 (7-37) represents <20% of total circulating endogenous GLP-1.
MOA highlights:
- How native GLP-1 works
- GLP-1 impairment and T2D
- How Victoza® helps address incretin impairment in adults with T2D
Learn about the mechanism of action of Victoza®
- There are no references associated with this video.